

The Management of HIV-Positive Pregnant Women

Goals of Antiretroviral Therapy

Treatment of mother

Protection of fetus





Timing of Transmission 1/3 2/3 peripartum Antepartum (in utero) 3

Variables Associated with Perinatal Transmission

> Viral Factors

- Maternal HIV RNA level
- Strain Variation
- Plasma vs. Genital tract viral load
- Genotypic Resistance

> Maternal

- STDs
- Vitamin A Deficiency
- CD4 cell count
- Substance abuse
- Cigarette smoking
- Use of Antiretrovirals
- Sexual Behavior

> Obstetrical Factors

- Duration of Ruptured Membranes
- Placental disruptionincluding abruption or chorioamnionitis
- Invasive fetal monitoring
- Episiotomy, forceps
- Vaginal Delivery
- Fetal Factors
 - Immature immune system
 - Gestational Age at delivery

> Breastfeeding

Variables Associated with Perinatal Transmission

Viral Factors

- Maternal HIV RNA level
- Strain Variation
- Plasma vs. Genital tract viral load
- Genotypic Resistance


Maternal

- STDs
- Vitamin A Deficiency
- CD4 cell count
- Substance abuse
- Cigarette smoking
- Use of Antiretrovirals
- Sexual Behavior


Obstetrical Factors

- Duration of Ruptured
 Membranes
- Placental disruption-including abruption or chorioamnionitis
- Invasive fetal monitoring
- Episiotomy, forceps
- Vaginal Delivery
- Fetal Factors
 - Immature immune system
 - Gestational Age at delivery
- > Breastfeeding

Perinatal Transmission Rate by Maternal HIV-1 RNA - WITS



Rate of Perinatal HIV-1 Transmission by ARV Therapy category



AZT

- Placental passage of AZT is excellent
- That of other ARVs is variable
- When combination ARV therapy is initiated during pregnancy, AZT should be included as a component of antenatal therapy whenever possible
- If antenatal AZT use is not possible, at least one agent with known transplacental passage should be part of the ARV regimen


Combination Therapy

Two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)

plus


protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or integrase inhibitor

Optimal Intervention = Prevention of Transmission



Wade, et al. 1998 NEJM 339;1409-14 Guay, et al. 1999 Lancet 354;795-802 Fiscus, et al. 2002 Ped Inf Dis J 21;664-668 Moodley, et al. 2003 JID 167;725-735

Acute HIV Infection



Seroconversion in Pregnancy

Most seroconversions in pregnancy are not detected

Viremia associated with acute infection increases risk of MTCT

Many national guidelines do not recommend combination therapy for women with high CD4

Generally few national guidelines for acute infection in pregnancy exist

IMPLICATIONS FOR ASPIRE



Implications for ASPIRE

Pregnant women who seroconvert

- Monthly HIV testing will lead to prompt diagnosis
- These women will have high viral loads and high CD4 counts
- National guidelines in place may not recommend combination therapy
- It is our ethical obligation to see that our participants get optimal care

Implications for ASPIRE Pregnancy + Seroconversion

Immediate Combination Therapy

Implications for ASPIRE

Your site will have to negotiate with HIV providers

Please notify PSRT of these situations



Implications for ASPIRE

Seroconverters who become pregnant

Monthly pregnancy testing will lead to prompt diagnosis

 Imperative that these women receive antiretrovirals in accordance with your national standard of care for the prevention of MTCT

Please notify PSRT of these situations

What Are Your Plans?

